An expanded access record providing Rufinamide in Lennox Gastaut Syndrome, sponsored by Eisai Inc.. Available at 2 sites in Poland. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Eisai Inc. · Expanded access
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 14 are open to participants now.
Browse Lennox Gastaut Syndrome studies →Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.